Argan, Inc. (AGX)

NYSEIndustrialsEngineering & ConstructionSnapshot 2026-10-23

$331.03+0.22%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Argan, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-10-31
Revenue	—	358.78M
EPS	—	3.135
Annual ending 2027-01-31
Revenue	—	1.4B
EPS	—	13.215
Annual ending 2028-01-31
Revenue	—	1.69B
EPS	—	15.773

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Quarterly dividend maintained at $0.50 per share	The company increased its dividend from $0.375 to $0.50 per share.	Intact	dividend falls below $0.38 per share	Dividend per share: $0.50 per share FY2027-Q2; GAAP. Published target: >=0.50 USD per share. The stored target says 2026-Q2; this source reports FY2027-Q2. Fiscal/calendar alignment needs review. Source published Sep 2, 20260.5 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q2 · Period ending Jul 31, 2026 Source: company_financial_results. Reference: dca862a9-97c0-460f-9ebf-d37101a7c888. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Operating income improves to at least $45.4 million	Profit improved with operating income rising from $30.1M to $45.4M.	Improving	operating income falls below $30.1 million	Operating income: $56.805M FY2027-Q2; GAAP. Published target: >=45.4 million USD. The stored target says 2027-Q1; this source reports FY2027-Q2. Fiscal/calendar alignment needs review. Source published Sep 2, 202656,805,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q2 · Period ending Jul 31, 2026 Source: company_financial_results. Reference: dca862a9-97c0-460f-9ebf-d37101a7c888. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 3 of last 3 quarters. Operating income rose from $32.7M in 2026-Q1 to $45.4M in 2026-Q2, with gross margin improving from 20.5% to 21.0%. Net income also increased, reflecting management's delivery on profitability improvement through strong execution. Delivery assessment Oct 24, 2026
Project backlog reaches at least $2.9 billion	Argan grows revenue by expanding its project backlog from $1.4B to $2.9B.	Intact	project backlog falls below $1.4 billion	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 3 of last 3 quarters. Revenue increased from $193.7M in 2026-Q1 to $291.0M in 2026-Q2 (+50.2%), reflecting strong execution and backlog growth. Project backlog was $2.9B at 2026-Q1 and slightly declined to $2.8B at 2026-Q2. Management is delivering revenue growth consistent with its backlog focus, though backlog showed a modest decline recently. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-01-31 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue$1.69B

Unavailable → $1.69B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	3 / 4
2026-07-25	Unavailable	Unavailable	3 / 4
2026-07-26	Unavailable	Unavailable	3 / 4
2026-07-27	Unavailable	Unavailable	3 / 4
2026-07-28	Unavailable	Unavailable	3 / 4
2026-07-29	Unavailable	Unavailable	3 / 4
2026-07-30	Unavailable	Unavailable	3 / 4
2026-07-31	Unavailable	Unavailable	3 / 4
2026-08-01	Unavailable	Unavailable	3 / 4
2026-08-02	Unavailable	Unavailable	3 / 4
2026-08-03	Unavailable	Unavailable	3 / 4
2026-08-04	Unavailable	Unavailable	3 / 4
2026-08-05	Unavailable	Unavailable	3 / 4
2026-08-06	Unavailable	Unavailable	3 / 4
2026-08-07	Unavailable	Unavailable	3 / 4
2026-08-08	Unavailable	Unavailable	3 / 4
2026-08-09	Unavailable	Unavailable	3 / 4
2026-08-10	Unavailable	Unavailable	3 / 4
2026-08-11	Unavailable	Unavailable	3 / 4
2026-08-12	Unavailable	Unavailable	3 / 4
2026-08-13	Unavailable	Unavailable	3 / 4
2026-08-14	Unavailable	Unavailable	3 / 4
2026-08-15	Unavailable	Unavailable	3 / 4
2026-08-16	Unavailable	Unavailable	3 / 4
2026-08-17	Unavailable	Unavailable	3 / 4
2026-08-18	Unavailable	Unavailable	3 / 4
2026-08-19	Unavailable	Unavailable	3 / 4
2026-08-20	Unavailable	Unavailable	3 / 4
2026-08-21	Unavailable	Unavailable	3 / 4
2026-08-22	Unavailable	Unavailable	3 / 4
2026-08-23	Unavailable	Unavailable	3 / 4
2026-08-24	Unavailable	Unavailable	3 / 4
2026-08-25	Unavailable	Unavailable	3 / 4
2026-08-26	Unavailable	Unavailable	3 / 4
2026-08-27	Unavailable	Unavailable	3 / 4
2026-08-28	Unavailable	Unavailable	3 / 4
2026-08-29	Unavailable	Unavailable	3 / 4
2026-08-30	Unavailable	Unavailable	3 / 4
2026-08-31	Unavailable	Unavailable	3 / 4
2026-09-01	Unavailable	Unavailable	3 / 4
2026-09-02	Unavailable	Unavailable	3 / 4
2026-09-03	Unavailable	Unavailable	3 / 4
2026-09-04	Unavailable	Unavailable	3 / 4
2026-09-05	Unavailable	Unavailable	3 / 4
2026-09-06	Unavailable	Unavailable	3 / 4
2026-09-07	Unavailable	Unavailable	3 / 4
2026-09-08	Unavailable	Unavailable	3 / 4
2026-09-09	Unavailable	Unavailable	3 / 4
2026-09-10	Unavailable	Unavailable	3 / 4
2026-09-11	Unavailable	Unavailable	4 / 4
2026-09-12	Unavailable	$1,684,821,333	4 / 5
2026-09-13	Unavailable	$1,684,821,333	4 / 5
2026-09-14	Unavailable	$1,684,821,333	4 / 5
2026-09-15	Unavailable	$1,684,821,333	4 / 5
2026-09-16	Unavailable	$1,684,821,333	4 / 5
2026-09-17	Unavailable	$1,684,821,333	4 / 5
2026-09-18	Unavailable	$1,684,821,333	4 / 5
2026-09-19	Unavailable	$1,684,821,333	4 / 5
2026-09-20	Unavailable	$1,684,821,333	4 / 5
2026-09-21	Unavailable	$1,684,821,333	4 / 5
2026-09-22	Unavailable	$1,684,821,333	4 / 5
2026-09-23	Unavailable	$1,684,821,333	4 / 5
2026-09-24	Unavailable	$1,684,821,333	4 / 5
2026-09-25	Unavailable	$1,684,821,333	4 / 5
2026-09-26	Unavailable	$1,684,821,333	4 / 5
2026-09-27	Unavailable	$1,684,821,333	4 / 5
2026-09-28	Unavailable	$1,684,821,333	4 / 5
2026-09-29	Unavailable	$1,684,821,333	4 / 5
2026-09-30	Unavailable	$1,684,821,333	4 / 5
2026-10-01	Unavailable	$1,687,321,333	4 / 5
2026-10-02	Unavailable	$1,687,321,333	4 / 5
2026-10-03	Unavailable	$1,687,321,333	4 / 5
2026-10-04	Unavailable	$1,687,321,333	4 / 5
2026-10-05	Unavailable	$1,687,321,333	4 / 5
2026-10-06	Unavailable	$1,687,321,333	4 / 5
2026-10-07	Unavailable	$1,687,321,333	4 / 5
2026-10-08	Unavailable	$1,687,321,333	4 / 5
2026-10-09	Unavailable	$1,687,321,333	4 / 5
2026-10-10	Unavailable	$1,687,321,333	4 / 5
2026-10-11	Unavailable	$1,687,321,333	4 / 5
2026-10-12	Unavailable	$1,687,321,333	4 / 5
2026-10-13	Unavailable	$1,687,321,333	4 / 5
2026-10-14	Unavailable	$1,687,321,333	4 / 5
2026-10-15	Unavailable	$1,687,321,333	4 / 5
2026-10-16	Unavailable	$1,687,321,333	4 / 5
2026-10-17	Unavailable	$1,687,321,333	4 / 5
2026-10-18	Unavailable	$1,687,321,333	4 / 5
2026-10-19	Unavailable	$1,687,321,333	4 / 5
2026-10-20	Unavailable	$1,687,321,333	4 / 5
2026-10-21	Unavailable	$1,687,321,333	4 / 5
2026-10-22	Unavailable	$1,687,321,333	4 / 5
2026-10-23	Unavailable	$1,687,321,333	4 / 5
2026-10-24	Unavailable	$1,687,321,333	4 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	2	3	0
2026-06-01	2	3	0
2026-07-01	2	3	0
2026-08-01	2	3	0
2026-09-01	4	3	1
2026-10-01	4	1	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 4 Buy / Strong Buy · 1 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Quarterly dividend maintained at $0.50 per shareDividend per share: $0.50 per share
Operating income improves to at least $45.4 millionOperating income: $56.805M
Project backlog reaches at least $2.9 billionDirect metric needs a verified mapping

Next proof point

Dec 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.6%Typical daily move · historical

Downside history

-58.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Argan, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

AGX is an execution-led industrial growth story, supported by project backlog and robust earnings quality. The multi-year view is intact, but risk is elevated and the industrial sector backdrop is a headwind.

What's priced into Argan, Inc.

The evidence describes AGX as cheap versus peers, with expectations below the model’s view and low pricing fragility. This suggests the market is not demanding especially strong results, though the valuation evidence is based on a high-confidence model.

What the fundamentals likely do

Near term, revenue execution has been strong: quarterly revenue rose from $193.7 million to $291.0 million, while backlog edged down from $2.9 billion to $2.8 billion. Management has consistently raised the dividend, and the recent acquisition may expand Teledata, but its growth impact is not yet demonstrated. A guidance cut or weaker industry conditions would challenge the near-term picture.

What Argan, Inc. hinges on

The multi-year thesis hinges on continued conversion of backlog into revenue without a sustained decline in project work. Near term, AGX guidance and results from sector bellwethers PWR, FIX, and EME are key signals. A guidance cut or weaker peer results would weaken the setup, while continued peer strength could support the industrial backdrop.